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INTRODUCTION
In patients with chronic pancreatitis, characterized by
progressive and irreversible pancreatic injury, the aims of
endoscopic therapy are to alleviate outflow obstruction of
the pancreatic duct (PD), thereby decreasing ductal hyper-
tension; to drain fluid collections; to divert flow away from
the fistula/leak; and to relieve pain. Among the available
endoscopic modalities, endoscopic retrograde cholan-
giopancreatography (ERCP) is used to treat pancreatic
strictures, pancreatic ductal stones, pseudocysts, PD
fistulas/leaks, and bile duct strictures. Data are accu-
mulating concerning the outcome following endoscopic
therapy in chronic pancreatitis [1]. In a large series of
1000 patients with chronic pancreatitis who were treated
endoscopically, with long-term follow-up, 65% of the
patients with strictures and/or stones showed improvement
in pain after endotherapy [2]. Endoscopic intervention
consisted of PD stricture dilatation, stone extraction, or
PD sphincterotomy. Endoscopic ultrasound (EUS) can
be used to pseudocyst drainage, perform celiac plexus
neurolysis or block to improve pain. Jejunal tube placement
for enteral feeding may be used for gut rest and to decrease
pancreas stimulation.
Pancreatic endotherapy should be considered in patients
in whom medical treatment or dilation of the main PD has
failed to elicit a favorable response. Although most studies
have suggested that endotherapy does not improve
pancreatic function, one secretin-enhanced magnetic
resonance cholangiopancreatography study suggested
that pancreatic exocrine function can improve after
endoscopic therapy [3].
Pancreatic sphincterotomy
Pancreatic sphincterotomy can be performed with a
needle-knife incision over a guiding pancreatic stent or
with a pull-type sphincterotome passed over a guidewire.
This can be used to treat manometrically documented
or suspected pancreatic sphincter of Oddi dysfunction
(SOD). However, most pancreatic sphincterotomies are
performed as a part of pancreatic stone, stricture, or
pseudocyst management, or combined pancreatobiliary
sphincterotomy for SOD. After such sphincterotomy, a 3
Fr single pigtail plastic stent, 4 to 6 cm in length, is used to
prevent post-procedure pancreatitis, unless a larger
diameter stent is required for treatment of a simultaneous
stricture. The small-diameter single pigtail stent generally
passes into the gastrointestinal tract within 7-14 days
without the need for a second endoscopic procedure for
stent retrieval. Risks of pancreatic sphincterotomy include
early complications of pancreatitis (2-7%), bleeding (0-
3%), and perforations (<1%), and late complications of
sphincter stenosis (up to 10%) [4].
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REVIEWDilation and stenting of pancreatic strictures
Benign strictures of the main PD are generally due to
inflammation or fibrosis around the main PD. Focal
strictures of the pancreatic head or body can be approached
by endoscopic dilation and/or stent placement. Cases in
which the narrowing involves the sphincter per se are
classified as SOD and are best diagnosed by manometry.
Patients with focal head/body strictures with upstream
dilation are the best candidates for the endoscopic
management of pancreatic stricture, whereas patients
with complex strictures and associated stones, pseudocysts,
inflammatory mass of the head, or diffuse ductal changes
are poor candidates.
In most patients, pancreatic sphincterotomy (with or
without a biliary sphincterotomy) via the major or minor
papilla is performed to facilitate placement of accessories
or stents. A guidewire must be maneuvered upstream to
the narrowing before stenting or dilation of the stricture
with a balloon or dilating catheter. High-grade strictures
require dilation prior to insertion of the endoprosthesis
(Fig. 1). This may be performed with graduated dilating
catheters or hydrostatic balloon dilating catheters. PD
strictures from chronic pancreatitis are often densely
fibrotic, and thus simple balloon dilation alone does not
generally result in a satisfactory long-term response.
Therefore, one or more PD stents are placed through the
strictures to chronically expand the lumen (Table 1). The
goals of pancreatic stenting are 1) to adequately expand
the narrowing so that it allows good flow long after the
stent is removed, and 2) to predict the response to surgical
drainage if necessary. In general, the diameter of the stent
should not exceed the downstream duct diameter. Stent
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Table 1. Result of pancreatic duct stenting in dominant pancreatic duct strictures (10 Series; 1988-2005) 
Number of patients Technical success rate Follow-up Patients improved rate Major complications Mortality
525 91% 34 62% 18% 1%
Figure 1. The procedure of endoprothesis insertion for the high-grade pancreatic duct stricture. (A) Severe main pancreatic duct
stricture is seen at the head portion. (B) The main pancreatic duct stricture is dilated with balloon catheter. (C, D, E) Multiple plastic
stents are inserted in the main pancreatic duct.
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calibers range from 3 to 10 Fr are usually used. For pan-
creatitis prophylaxis, 3-5 Fr stents are usually used;
stricture therapy usually requires single or multiple 7, 8.5,
or 10 Fr stents.
In a prospective study, Weber et al. investigated clinical
success rates in 19 patients after initial ERCP and relapse
rates during a 2 year follow-up period [5]. The overall
patient assessment of stent therapy revealed complete
satisfaction in 17 of 19 patients. A relapse rate of approxi-
mately 30% was seen within 2 years after stent extraction,
and relapse was treated by repeated stent therapy. At 5
year follow-up, another series reported pain relief in
65% of patients with ductal outflow obstruction due to
dominant PD stricture that was treated by stent drainage
[6]. Costamagna et al, studied 19 patients with severe
chronic pancreatitis and with a single pancreatic stent
through a refractory dominant stricture in the pancreatic
head with the following protocol: (i) removal of the single
pancreatic stent; (ii) balloon dilation of the stricture; (iii)
insertion of the maximum number of stents allowed by
the stricture tightness and PD diameter; and (iv) removal
of the stents after 6-12 months [7]. They reported that the
median number of stents placed through the major or
minor papilla was three, with diameters ranging from
8.5 to 11.5 Fr and lengths ranging from 4 to 7 cm. Only one
patient (5.5%) had persistent stricture after multiple
stenting. During a mean follow-up of 38 months after
removal, 84% of the patients were asymptomatic, and
10.5% had symptomatic stricture recurrence.
Benign stricture of the main PD is usually managed with
placement of one or multiple plastic stents. There have
been several trials using metal stents for benign strictures
of the PD (Fig. 2). Eisendrath et al. inserted self-expandable,
uncovered Wallstents (n=20) and partially or totally
covered Wallstents (n=18) in patients with chronic pan-
creatitis associated with dominant stricture of the main
PD [8]. The results using uncovered Wallstents were
unsatisfactory because of frequent stent dysfunction
caused by tissue ingrowth (65%) through the wire mesh.
In cases using partially or totally covered stents, epithelial
hyperplasia and stent migration were the major late
complications. They concluded that self-expandable
stents provided disappointing results. Park et al. used fully
covered, self-expandable metal stents for refractory
benign pancreatic stricture in 13 patients [9]. The stents
were left in place for 2 months in nine of 13 patients. Early
migration occurred in five patients (39%; 1 proximal and 4
distal). In all nine patients, the stents were successfully
removed after 2 months, and patients were followed for a
median period of 5 months (2-10 months). During the
follow-up period, there was no pain relapse in any of the
patients. However, further long-term randomized studies
of the use of metal stents in benign lesions of the pancreas
are required.
In a recent randomized trial comparing endoscopic
transampullary drainage of the PD and operative
pancreaticojejunostomy, complete or partial pain relief
was achieved in 32% of the patients receiving endoscopic
drainage as compared with 75% of the patients receiving
surgical drainage (p=0.007) [10]. The rate of complications,
length of hospital stay, and changes in pancreatic function
were similar between the two treatment groups, but
patients receiving endoscopic treatment required more
procedures than those in the surgery group (median of 8
vs. 3, p<0.001). The investigators concluded that surgical
drainage of the PD was more effective than endoscopic
Figure 2. Insertion of metal stent in the main pancreatic
duct.treatment in patients with obstruction of the PD due to
chronic pancreatitis.
Occasionally, PD strictures are very tight or angulated
and may not be traversable with conventional dilators and
catheters. Familiari et al. described the placement of a
guidewire (used as a dilator) across these types of strictures
for 24 hours [11]. They hypothesized that the guidewire,
left in place across the stricture, in combination with its
slight movements caused by breathing, facilitated
noninvasive dilation of the stenosis and allowed
subsequent mechanical dilation and stent insertion. We
have had similar good outcomes in five patients.
The optimum duration of stent placement, stent number
and diameter, and degree of balloon dilation are not well
known. Michael et al. attempted to identify endoprosthesis-
or patient-related risk factors for pancreatic stent occlusion
in patients with chronic pancreatitis [12]. However, the
clinical and laboratory data did not reliably indicate
clogging. Therefore, they recommended stent removal
or exchange within 3 months in high-risk patients.
Alternatively, some centers leave stents in situ until
symptoms recur. Patients with chronic pancreatitis have
elevated risk for pancreatic cancer. Endoscopists must
maintain a high index of suspicion of underlying cancer
whenever treatment of a PD stricture is performed and
should obtain appropriate tissue samples [13].
The early complications of stent placement (bleeding
and pancreatitis) are similar to those of sphincterotomy.
Late complications are mainly related to stent migration
and occlusion, which present with pain, pancreatitis, or
infection [14]. In addition, PD stents may produce ductal
changes, including strictures or focal areas of chronic
pancreatitis [15,16]. However, these changes may improve
with time.
Removal of pancreatic duct stones
Obstructing pancreatic stones may contribute to
abdominal pain or acute pancreatitis in patients with
chronic pancreatitis. Approximately 10-25% of pancreatic
stones can be removed effectively by standard techniques,
with a balloon and/or basket [17]. The best candidates for
endoscopic removal of PD stones are main duct stones of
the head or body with upstream main PD dilation (Fig. 3).
Patients with extensive stones of the whole gland or side
branch duct stones without main PD dilatation are poor
candidates for endoscopic removal of PD stones.
Simple stone extraction can be achieved by various
techniques, including balloon or basket sweep. Larger
stones usually require lithotripsy via extracorporeal
shockwave lithotripsy (ESWL) followed by balloon or
basket sweep, mechanical lithotripsy, intracorporeal
lithotripsy with a pulse-dye laser or electrohydraulic
lithotripsy (EHL), or surgery [18].
ESWL has been used to facilitate the removal of PD
stones during therapeutic endoscopy (Fig. 4, Table 2).
Patients frequently require several ESWL sessions to
achieve stone clearance from the duct [19]. Some investi-
gators have reported high success rates of stone clearance
with ESWL, whereas others have had less impressive
results [20,21]. In a nonrandomized study, Dumonceau et
al. compared pain relief in 55 patients with painful
calcified chronic pancreatitis after ESWL alone (n=26)
and after ESWL combined with endoscopic drainage of
the main PD (n=29) [22]. After one month, diameter of
main pancreatic duct was significantly decreased. The
number of pain episodes during the year after treatment
decreased markedly in both groups, and the difference
between both groups was not significant. Two years after
treatment, the rates of pain relapse were 38% in the
ESWL group and 45% in the ESWL plus endoscopy
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Figure 3. Endoscopic removal of main pancreatic duct stones. (A) Multiple filling defects are seen in the main pancreatic duct of the
pancreas head. (B) The stones are removed with basket after endoscopic pancreatic sphincterotomy. (C) Dilated main pancreatic duct is
seen after complete removal of stones.
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group. The presence of obstructive calcifications in the
head of the pancreas was the only factor independently
associated with the absence of pain relapse. There was no
procedure-related mortality, and only one procedure-
related complication (a pseudocyst treated successfully
by endoscopy) was seen. Treatment costs per patient
in the ESWL plus endoscopy group were about threefold
the costs in the ESWL alone group. The investigators
concluded that ESWL alone is a safe and effective preferred
treatment for selected patients with painful calcified
chronic pancreatitis. Intraductal lithotripsy guided by
pancreatoscopy has also been used to fragment PD stones.
In a large series of patients, pain relief was achieved in 70-
80% of patients after stone removal, and the pain relapse
rate was approximately 30% over 2 years [2].
Surgical removal of PD stones can also be achieved. In
one randomized trial of endoscopic and surgical therapies,
surgery was superior for long-term pain reduction in
patients with painful obstructive chronic pancreatitis, and
endotherapy without conjunctive ESWL appeared to be a
suboptimal approach for PD stone therapy [23]. Generally,
endotherapy is preferable as it is less invasive, and surgery
Table 2. Clinical results of endoscopy and ESWL for pancreatic duct stones (11 Series; 1992-2005) 
Number




pain relief in body weight Improved     Worsened Improved     Worsened
1041 79% 61.8% 55.6%           32.5% 16.5%          19.6% 7.9% 31.7%
Figure 4. Extracorporeal shockwave lithotripsy (ESWL) to facilitate the removal of pancreatic duct stones. (A) Huge calcified stone is
seen in the pancreas. (B) Fragmented Pancreatic duct stones are seen after ESWL. (C) Fragmented stones are removed with forceps. (D)
Dilatated main pancreatic duct is seen after complete removal of stones.
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C Dis considered a second-line therapy for patients in whom
endoscopic therapy fails. Improvements in pain (77-100%
and 54-86%, respectively) have been reported in some
short-term and long-term follow-ups, to 5 years [24,25].
In the author’s experience, approximately 50% of patients
have pain relapse within a 5 year follow-up period. This
may be caused by new stone formation or underlying
ongoing pancreatitis.
Biliary obstruction in chronic pancreatitis
Distal common bile duct stricture has been reported in
at least 35% of patients with chronic pancreatitis [26-28].
These strictures result from a fibrotic inflammatory
restriction or compression by a pseudocyst. The anatomical
relationship of the common bile duct with the head of the
pancreas is an important factor influencing the nature of
the stenosis in chronic pancreatitis [29]. Common bile
duct stricture occurs as a consequence of recurrent acute
inflammatory episodes, which may ultimately result
in periductal fibrotic stricture [30]. This is seen more
commonly in advanced chronic pancreatitis in calcific
variants with calcifications [31,32].
Jaundice occurs in 30-50% of stricture patients and
may be transient, recurrent, or persistent [30,33]. Transient
jaundice is typically seen during acute exacerbation and
recedes with resolution of the inflammatory process [34].
The most commonly used laboratory test is the deter-
mination of an elevated alkaline phosphatase (ALP) level
[27]. A persistent increase of ALP, greater than twofold for
more than 1 month, has been proposed as a specific marker
of bile duct stricture [35]. We favor no treatment unless
the ALP is ≥2×normal with ductal dilation.
Most studies have shown that cholestasis can be
effectively resolved in the short-term setting by ERCP
plastic biliary stenting [36,37]. Before attempting
endoscopic treatment, it is necessary to ensure that the
bile duct stricture is not the result of pancreatic cancer.
Endoscopic ultrasound-guided fine-needle aspiration
(EUS-FNA) is required to exclude the possibility of cancer.
The risk for pancreatic cancer is increased in patients
with chronic pancreatitis, although the magnitude of the
increase is uncertain [38,39].
Chronic obstruction of the common bile duct may cause
hepatic fibrosis and secondary biliary cirrhosis [40,41].
Hemmel et al. studied liver biopsy specimens from 11
patients with chronic stenosis of the common bile duct
attributable to chronic pancreatitis [41]. All patients had
undergone liver biopsy before and after the insertion of
biliary drainage. Patients without restenosis showed
improvement of hepatic fibrosis after biliary drainage. In
our experience, these strictures do not commonly resolve,
and long-term stenting, or preferably surgical bypass, is
needed. Preliminary experience with the placement of 4-8
cm, 10 Fr plastic stents has suggested better long-term
patency. Fully coated metal stents placed at ERCP are
being evaluated for treatment of these strictures. To be
successful, it is essential that these stents be removable
after 6-24 months in situ and cause no ductal injury. Van
Berkel et al. reported that the use of self-expanding metal
stents for long-term stenting of benign biliary strictures
due to chronic pancreatitis was safe and that it provided
successful and prolonged biliary drainage in a selected
group of patients in whom surgical intervention was not
possible or desirable [42]. Larger, prospective, randomized,
long-term studies are required to confirm these results.
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Figure 5. Disruption of the main pancreatic duct.  (A) Partial pancreatic duct disruption. (B) Complete pancreatic duct disruption.
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Pancreatic duct leaks
PD disruptions or leaks can occur from a blowout
upstream of obstructing strictures or stones in chronic
pancreatitis [43-45]. Disruption of the main pancreatic
duct (MPD) may be partial or complete (Fig. 5). On ERCP,
partial disruption appears as fluid collection communi-
cating directly with the MPD. Complete disruption
consists of MPD transection, leading to pancreatic ascites,
pleural effusions, pseudocyst formation, and internal and
external pancreatic fistulas. PD leaks can often be treated
with endoscopic placement of transpapillary stents.
Varadarajulu et al. performed a study in 97 patients with
PD disruptions to identify predictors of outcome after
endoscopic transpapillary stent insertion, and univariate
analysis showed that endoscopic therapy was successful in
closing the leak in approximately 60% of the patients [46].
Factors associated with a better outcome included partial
disruption, successful bridging of the disruption with a
stent, and longer duration of stent placement (approxi-
mately 6 weeks). On multivariate analysis, partial pancreatic
disruption and a stent bridging the disruption were
correlated with a successful outcome. There have been no
comparative studies of surgical, medical, or endoscopic
therapy for the treatment of PD leaks.
Treatment of chronic pancreatitis due to pancreas
divisum
Opening the minor papilla by sphincterotomy and the
combined sphincterotomy/stenting technique has been
shown to eliminate recurrent pancreatitis in 75% of
patients with chronic pancreatitis and to improve pain in
approximately 50% of those with pain syndrome. Vitale et
al. evaluated the long-term efficacy of endoscopic stenting
in 24 patients with chronic pancreatitis due to pancreas
divisum, who were followed for a mean period of 59.6
months [47]. The mean pain score and number of hospital
admissions decreased significantly after stent placement.
Pain medication usage decreased in 58% of the patients,
remained the same in 21%, and increased in 13%. The
authors concluded that endoscopic stenting of the PD is a
safe and effective first-line treatment for patients with
pancreatitis secondary to pancreas divisum.
Endoscopic jejunal tube placement for enteral
feeding
In patients with unrelenting pain from chronic pan-
creatitis, gut rest by either enteral feeding (preferred) or
parenteral nutrition can be recommended. By feeding the
gut beyond the ligament of Treitz, enteral feeding causes
negligible stimulation of the pancreas and is associated
with improved immune function, reduced infections, and
lower pain scores. Short-term feeding can be accomplished
with a nasojejunal tube. For longer-term feeding in patients
with frequent vomiting, a combination gastrostomy and
jejunostomy tube is often used. However, patients who
vomit up their jejunostomy tube require a direct jejunos-
tomy tube placed laparoscopically or endoscopically.
Celiac nerve block and neurolysis
Celiac plexus block or neurolysis can be performed to
improve pain in patients with chronic pancreatitis. Celiac
plexus block involves injection of a steroid (triamcinolone)
and an anesthetic agent (bupivacaine) into the celiac
plexus, and celiac plexus neurolysis involves injection of
a neurolytic agent (absolute alcohol) into the celiac plexus
to ablate or destroy the ganglia, thereby interrupting pain
transmission. EUS can be used in patients with a sub-
optimal response to medical management. In general,
EUS-guided celiac plexus block improves pain in about
50% of patients for a period of 3-6 months. Younger
patients (<45 years old) and those with previous pancreatic
surgery were less likely to respond to EUS-guided celiac
plexus block [48].
Complications of celiac plexus block or neurolysis are
infrequent and mostly self-limiting. The most common
side effects are transient diarrhea and hypotension, which
may occur in 30-40% of patients. Sympathetic blockade
can manifest as diarrhea and hypotension because of
the relatively unopposed visceral parasympathetic activity.
In most patients, diarrhea is mild and self-limiting, lasting
for less than 48 hours. Major complications, including
retroperi- toneal bleeding and peripancreatic abscess, have
been reported infrequently. It is advisable to administer
antibiotic prophylaxis (against mouth flora) to patients
undergoing celiac plexus block. Antibiotics may not be
necessary when alcohol is used, owing to the inherent
bactericidal properties of alcohol. However, ethanol causes
a dense desmoplastic reaction, making any future
pancreatic surgery more difficult. Therefore, we avoid
alcohol neurolysis for chronic pancreatitis, because these
patients may require future surgery. As celiac block is of
clinical benefit in only ~50% of patients, we use EUS-
guided block when EUS is being performed for diagnostic
reasons or in patients who would benefit from a vacation
from pain or pain medications.Pancreatic pseudocysts
Pancreatic pseudocysts (PPs), arising from duct
disruption in areas of inflammation or necrosis, develop in
approximately 20-40% of patients with chronic pancre-
atitis. Pseudocysts may be located within or outside the
pancreas, may be single or multiple, may occur with or
without persistent connection to the ductal system duct,
and may be symptomatic or asymptomatic. The treatments
of choice are surgery, external drainage, and endoscopic
cyst-enteric drainage, as well as conservative treatment for
selected candidates. Intervention is indicated for PPs that
are symptomatic, in a phase of growth, or complicated
(infected, hemorrhage, biliary, or bowel obstruction), or in
those occurring together with chronic pancreatitis and
when malignancy cannot be unequivocally excluded [49].
Many factors such as the amount of necrosis, suspicion of
main PD disruption, the size of the pseudocyst, bulging on
the gut lumen, ductal communication, coagulopathy
/portal hypertension, tolerance to multiple procedures,
and symptoms can affect PPs management. Symptomatic
and large pseudocysts (>7 cm) generally require drainage
by endoscopic, surgical, or percutaneous approaches [50].
Percutaneous drainage is preferred for fluid collection
outside the pancreas without associated necrosis (low
probability of persistent ductal disruption).
The best candidates for endoscopic treatment of PPs are
those in which the cyst is bulging into the stomach or
duodenum, with an intact pancreas on abdominal CT or
ERCP and cysts arising from side branches. Poor candidates
for endoscopic treatment are PPs with organizing necrosis,
ductal disconnection, or immature fluid collection. An
endoscopic approach is used when a significant bulge is
noted against the lumen of the stomach or duodenum
(Fig. 6) and the distance between the gut wall and the
pseudocyst is less than 1 cm, with no intervening major
vascular structures. This entails the creation of a fistulous
tract between the PPs and the gastric lumen (cystogas-
trostomy) or the duodenal lumen (cystoduodenostomy). A
nasocystic catheter or a stent can be placed for continuous
drainage. The choice of a nasocystic catheter or stent for
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Figure 6. Endoscopic approach through the bulge in the lumen of the stomach or duodenum. (A) A pseudocyst bulging into gastric
wall. (B) Cyst puncture using cystotome resulting initial pus drainage. (C) Transmural (10-mm) balloon dilation. (D) Placement of one 7




B CYoo BM and Lehman GA. Update on endoscopic treatment of chronic pancreatitis    177
drainage depends on the appearance of the cyst contents.
A chronic cyst with clear liquid contents can be drained
with one or more stents. On the other hand, an infected
cyst may be aided by irrigation with a nasocystic catheter.
Arvanitakis et al. treated patients with chronic pancreatitis
with apparently complete disruption of the MPD by stent
placement into the PPs or peripancreatic fluid collection
[51]. Stent removal resulted in fluid reaccumulation, as the
duct disruption persisted, and the investigators
recommended long-term stenting. The authors, however,
prefer definitive surgical diversion. Transpapillary drainage
can also be performed when the pseudocyst connects to
the MPD above the stricture. Hookey et al. published a
comparative study on transmural and transpapillary
drainage in 116 patients with PPs [52]. The drainage
technique was transpapillary in 15 patients, transmural in
60, and both in 41. Successful resolution of symptoms and
collection occurred in 87.9% of the cases. No significant
differences were observed related to drainage technique
or drainage site. In a summary of eight series from the
literature, involving 311 patients, stent placement was
technically successful in 89% of the cases, with compli-
cations in 17% and death in 1%. Recurrences were seen in
10% and 20%, as observed in surgical series, and resulted
from persistent main duct disruption as noted above.
A web-based survey was sent to 3054 endoscopists
belonging to the American Society for Gastrointestinal
Endoscopy, and 266 (8.7%) responded. Among these, 198
reported performing pseudocyst drainage [53]. Drainage
was most commonly done by the transgastric route. The
number of stents placed ranged from 1 to 5, and these
remained in place for 2-30 weeks. A CT was used before
drainage by 95% of all respondents. EUS imaging was
used before drainage by 72 (70%) of 103 US endoscopists,
compared with 56 (59%) of 95 international endoscopists.
EUS-guided drainage was used by 56% of US endoscopists
and 43% of international endoscopists.
In conclusion, endoscopic transmural drainage is the
best technique for bulging PPs, whereas EUS-guided
drainage is required for non-bulging pancreatic collection
and in patients with portal hypertension (Table 3). For
patients with PPs due to complete disruption of the MPD,
surgical resection or diversion is preferred.
SUMMARY
Endoscopic management of chronic pancreatitis has
continued to evolve over the last decade. Enhanced
techniques, better patient selection for specific techniques,
and more comprehensive comparisons with surgery have
been reported. A team approach to these often difficult
cases is recommended.
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